Dear Editor, We thank Kolias et al. for their thoughtful comments on our publication. We actually concur with almost all points, especially that there is a need to generate level I evidence for this very common neurosurgical disorder. A randomised controlled trial will answer a lot of the questions raised in their comment. For the time being most things remain speculative and there are many options to treat chronic subdural haematomas. The one described by us is just one of them, which we prefer as first line treatment, primarily for its ease. We think we have shown approximately equivalent safety and efficacy in comparison to other methods. This was our goal. No less, no more.
